12/09/2025
A really exciting potential development for our pets with cancer!
✨ New Cancer Immunotherapy Trial Now Enrolling at Purdue ✨
Purdue University Veterinary Hospital is conducting a clinical trial evaluating a cutting-edge PD-L1 cancer vaccine designed to help a dog’s own immune system better recognize and destroy cancer cells.
This vaccine uses the same immune-checkpoint strategy that revolutionized cancer treatment in human medicine by blocking PD-L1, the “off switch” tumors use to hide from the immune system.
🐾 Enrolled dogs receive:
• Three vaccine treatments over 6 weeks
• Close monitoring by Purdue’s Oncology Service
• No placebos
• Access to a therapy developed specifically for dogs
🧬 Eligible cancers include:
T-zone lymphoma, melanoma, osteosarcoma, mast cell tumor, soft tissue sarcoma, squamous cell carcinoma, mammary carcinoma, and hepatocellular carcinoma.
📌 Dogs must be:
• Over 1 year old
• Over 18 lbs
• Able to undergo sedation
• Have tumors that can be biopsied
• Not currently on chemo, steroids, radiation, or targeted therapy
📅 Study duration: About 5 months
Owners must commit to all study visits and cannot pursue other treatments during participation.
📞 Questions or referrals? Contact Purdue Oncology at 765-494-1130 and mention “PD-L1 Immunotherapy Vaccine Trial.”
👉 Learn more about the clinical trial in the comments.
Purdue University American Veterinary Medical Association (AVMA) Purdue Institute for Cancer Research Indiana State Board of Animal Health IVMA: Indiana Veterinary Medical Association
